Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Chow BSM, Kocan M, Shen M, Wang Y, Han L, Chew JY, Wang C, Bosnyak S, Mirabito-Colafella KM, Barsha G, Wigg B, Johnstone EKM, Hossain MA, Pfleger KDG, Denton KM, Widdop RE, Summers RJ, Bathgate RAD, Hewitson TD, Samuel CS.

J Am Soc Nephrol. 2019 Sep 11. pii: ASN.2019060597. doi: 10.1681/ASN.2019060597. [Epub ahead of print]


NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.

Jha JC, Banal C, Okabe J, Gray SP, Hettige T, Chow BSM, Thallas-Bonke V, De Vos L, Holterman CE, Coughlan MT, Power DA, Skene A, Ekinci EI, Cooper ME, Touyz RM, Kennedy CR, Jandeleit-Dahm K.

Diabetes. 2017 Oct;66(10):2691-2703. doi: 10.2337/db16-1585. Epub 2017 Jul 26.


Angiotensin II type 2 receptor (AT2R) in renal and cardiovascular disease.

Chow BS, Allen TJ.

Clin Sci (Lond). 2016 Aug 1;130(15):1307-26. doi: 10.1042/CS20160243. Review.


The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.

Chow BS, Koulis C, Krishnaswamy P, Steckelings UM, Unger T, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Diabetologia. 2016 Aug;59(8):1778-90. doi: 10.1007/s00125-016-3977-5. Epub 2016 May 11.


Diabetes and Kidney Disease: Role of Oxidative Stress.

Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K.

Antioxid Redox Signal. 2016 Oct 20;25(12):657-684. Epub 2016 Apr 1. Review.


Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.

Jha JC, Thallas-Bonke V, Banal C, Gray SP, Chow BS, Ramm G, Quaggin SE, Cooper ME, Schmidt HH, Jandeleit-Dahm KA.

Diabetologia. 2016 Feb;59(2):379-89. doi: 10.1007/s00125-015-3796-0. Epub 2015 Oct 28.


Mouse Models for Studying Diabetic Nephropathy.

Chow BSM, Allen TJ.

Curr Protoc Mouse Biol. 2015 Jun 1;5(2):85-94. doi: 10.1002/9780470942390.mo140192.


AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy.

Koulis C, Chow BS, McKelvey M, Steckelings UM, Unger T, Thallas-Bonke V, Thomas MC, Cooper ME, Jandeleit-Dahm KA, Allen TJ.

Hypertension. 2015 May;65(5):1073-81. doi: 10.1161/HYPERTENSIONAHA.115.05204. Epub 2015 Mar 16.


Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.

Chow BS, Kocan M, Bosnyak S, Sarwar M, Wigg B, Jones ES, Widdop RE, Summers RJ, Bathgate RA, Hewitson TD, Samuel CS.

Kidney Int. 2014 Jul;86(1):75-85. doi: 10.1038/ki.2013.518. Epub 2014 Jan 15.


Mechanistic insights into the contribution of epithelial damage to airway remodeling. Novel therapeutic targets for asthma.

Royce SG, Li X, Tortorella S, Goodings L, Chow BS, Giraud AS, Tang ML, Samuel CS.

Am J Respir Cell Mol Biol. 2014 Jan;50(1):180-92. doi: 10.1165/rcmb.2013-0008OC.


Foot type biomechanics part 1: structure and function of the asymptomatic foot.

Hillstrom HJ, Song J, Kraszewski AP, Hafer JF, Mootanah R, Dufour AB, Chow BS, Deland JT 3rd.

Gait Posture. 2013 Mar;37(3):445-51. doi: 10.1016/j.gaitpost.2012.09.007. Epub 2012 Oct 26.


Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.

Chow BS, Chew EG, Zhao C, Bathgate RA, Hewitson TD, Samuel CS.

PLoS One. 2012;7(8):e42714. doi: 10.1371/journal.pone.0042714. Epub 2012 Aug 22.


Data compression by shape compensation for mobile video sensors.

Chow BS.

Sensors (Basel). 2009;9(4):2461-9. doi: 10.3390/s90402461. Epub 2009 Apr 9.

Supplemental Content

Support Center